Dr Agarwals Eye Hospital Ltd
Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]
- Market Cap ₹ 2,525 Cr.
- Current Price ₹ 5,224
- High / Low ₹ 7,300 / 3,500
- Stock P/E 40.1
- Book Value ₹ 651
- Dividend Yield 0.11 %
- ROCE 17.5 %
- ROE 29.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 32.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.2%
- Promoter holding has increased by 0.77% over last quarter.
Cons
- Stock is trading at 8.03 times its book value
- Company might be capitalizing the interest cost
- Promoters have pledged or encumbered 29.3% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | 430 | |
| 102 | 103 | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 277 | 295 | |
| Operating Profit | 11 | 15 | 18 | 23 | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 120 | 134 |
| OPM % | 9% | 13% | 13% | 15% | 16% | 18% | 27% | 22% | 29% | 28% | 29% | 30% | 31% |
| 3 | 0 | -5 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | 4 | |
| Interest | 4 | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 15 | 15 |
| Depreciation | 6 | 6 | 9 | 9 | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 | 42 |
| Profit before tax | 4 | 5 | -0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 | 82 |
| Tax % | 35% | -6% | -104% | 33% | 49% | 32% | 31% | 125% | 25% | 25% | 26% | 23% | |
| 2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | 63 | |
| EPS in Rs | 5.17 | 12.13 | 0.09 | 15.62 | 14.43 | 25.36 | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 | 116.28 | 132.85 |
| Dividend Payout % | 23% | 10% | 940% | 10% | 8% | 6% | 0% | 0% | 6% | 4% | 3% | 5% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 32% |
| 3 Years: | 31% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 85% |
| 3 Years: | 56% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 30% |
| 3 Years: | 33% |
| Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 14 | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 | 310 |
| 28 | 27 | 31 | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | 335 | |
| 20 | 18 | 24 | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | 79 | |
| Total Liabilities | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 729 |
| 26 | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | 409 | |
| CWIP | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 | 157 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 85 |
| 41 | 43 | 44 | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | 79 | |
| Total Assets | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 729 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | |
| -11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | |
| -3 | -5 | -0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | |
| Net Cash Flow | -2 | -1 | 0 | 0 | -0 | 2 | 2 | 15 | 7 | -1 | 6 | -22 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19 | 19 | 24 | 16 | 17 | 19 | 14 | 23 | 16 | 14 | 15 | 13 |
| Inventory Days | 96 | 238 | 200 | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 |
| Days Payable | 137 | 360 | 371 | 277 | 353 | 292 | 224 | 401 | 410 | 327 | 345 | 263 |
| Cash Conversion Cycle | -22 | -103 | -146 | -138 | -189 | -149 | -78 | -260 | -303 | -240 | -224 | -133 |
| Working Capital Days | -52 | -31 | -39 | -25 | -39 | -22 | -34 | -70 | -58 | -50 | -63 | -51 |
| ROCE % | 17% | 19% | 18% | 29% | 32% | 34% | 30% | 11% | 20% | 19% | 18% | 18% |
Documents
Announcements
- Corporate Action-Board approves Dividend 30 Oct
- Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025 30 Oct
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025 And Declaration Of Interim Dividend
30 Oct - Unaudited Q2/H1 results approved; interim dividend ₹3/share; record date Nov 07; payment by Nov 29, 2025.
- Corporate Action - Fixes Record Date As November 07, 2025 For The Purpose Of Interim Dividend , If Declared By The Board 27 Oct
-
Update on board meeting
27 Oct - Board meeting Oct 30, 2025 to approve Q2/H1 results and consider interim dividend; record date Nov 07, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025TranscriptNotesPPT
Services Offered
The company's centers offer comprehensive services in the eye-care segment including cataract, glaucoma, laser correction, corner and refractive, retina, squint, etc. [1]